Instil Bio Inc. (TIL) Appoints John Maraganore to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
June 11, 2025 7:00 AM EDTDALLAS, June 11, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Instil) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the addition of John Maraganore, Ph.D., to the Board of Directors of Axion Bio, Inc., Instils wholly-owned subsidiary dedicated to the development of AXN-2510 (2510), a potentially best-in-class PD-L1xVEGF bispecific antibody for solid tumors prioritizing front-line non-small cell lung cancer (NSCLC).
Johns appointment reflects our commitment to assembling world-class leadership to maximize the value of the 2510 program for patients and shareholders, and we have benefited greatly... More
